Apnimed Stock

Apnimed is a clinical-stage company dedicated to the discovery of novel pharmacologic therapies for sleep apnea and related disorders.

Sign up today and learn more about Apnimed Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Apnimed Stock

Apnimed is a clinical-stage company dedicated to the discovery of novel pharmacologic therapies for sleep apnea and related disorders. Sleep apnea is a common, serious condition with significant morbidity, increased mortality, and substantial effects on daily functioning. Sleep apnea affects more than 20 million Americans and has serious consequences. OSA is caused by a combination of predisposing anatomical factors and sleep-related decrements of activity in upper airway muscles. Current treatments primarily rely on positive pressure devices, e.g., CPAP, to maintain airway patency. Less commonly used treatments include mandibular advancement devices, nerve stimulation, and surgical interventions. Apnimed was founded in 2017 and is located in Cambridge, Massachusetts.

Funding History

June 2018$25.6M
March 2020$15.0M
March 2021$25.0M
May 2022$62.5M
December 2022$79.7M

Management

Founder, CEO & Board Chair

Lawrence G. Miller

Co-Founder and Medical Director

Luigi Taranto Montemurro

Board Member

Isaac Cheng

Board Member

Chris Dimitropoulos

M.D & Senior Vice President of Clinical Development

John Cronin

Chief Financial Officer

Michael Rogers

SVP, Medical Affairs

John Yee

Board Member

Stefan Larson

Chief Commercial Officer

Rob Rode

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo